Bionor Immuno AS Company Profile

06:41 EST 18th December 2018 | BioPortfolio

Bionor Immuno is a multidisciplinary drug discovery company located in Skien, Norway. The major focus of the company is to develop effective peptide based immunotherapies, against infectious diseases for which there is currently no effective vaccine or where existing treatments are poorly effective. Bionor Immuno AS aims to develop its therapeutic products through phase II clinical trials. Phase III clinical trials, manufacturing and marketing of finished products will be done in co-operation with a licensing partner


P.O. Box 1823


Phone: 47 35 50 57 50
Fax: 47 35 50 57 01

News Articles [276 Associated News Articles listed on BioPortfolio]

Silence Therapeutics names experienced biotech boss as its new chief executive officer with immediate effect

Dr David Horn Solomon was previously CEO of Zealand Pharma A/S, from 2008 to 2015, and has also been the CEO of Bionor Pharma ASA and Akari Therapeutics PLC

Immuno-Oncology Conference 2018

26 - 27 September, London, UK. Immuno-Oncology is a fast-paced field with massive potential to deliver successful and durable cancer therapies. SMi's Immuno-Oncology Conference will focus on a few key...

10 Top Immuno-Oncology Companies

One of the most highly anticipated methods to fight cancer is the immuno-oncology (I/O) sector. For investors interested in the field the Investing News Network (INN) has put together a list of top im...

New ASCO/SITC Guidance Addresses Shortcomings of Immuno-Oncology Trial Reporting

The recommendations on Trial Reporting in Immuno-Oncology aim to enchance understanding of efficacy and toxicity outcomes in immuno-oncology trials.

Manipulating microglia

Alector’s $133M series E will enable the immuno-neurology and immuno-oncology company to take five programs into the clinic.

Lilly and NextCure pen immuno-oncology deal

Eli Lilly & Co. and NextCure Inc. partnered to discover and develop new immuno-oncology therapies utilizing NextCure’s FIND-IO (Functional, Integrated, NextCure Discovery in Immuno Oncology) platfor...

ESMO Immuno-Oncology Congress showcases new technologies set to improve cancer treatment

(European Society for Medical Oncology) Innovation in immuno-oncology is exploding and new technologies that are set to benefit many patients with cancer are being showcased in the highly diverse arra...

GSK Funds a New Startup with Immunometabolic Focus

A new biopharmaceutical company known as Sitryx launched with $30 million in a Series A funding round to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation.

Drugs and Medications [0 Results]


PubMed Articles [68 Associated PubMed Articles listed on BioPortfolio]

Challenges in Immuno-Oncology - Possibilities for Optimization.

Immuno-oncology has undoubtedly started a new era in the treatment of malignant diseases. Within a short time immunotherapeutic therapy concepts have become part of the standard therapy for many tumor...

Demonstration of IgG Subclass (IgG1 and IgG3) in Immuno-Related Hemocytopenia.

Immuno-related hemocytopenia (IRH) is defined as idiopathic cytopenia of undetermined significance (ICUS) patients with autoantibodies. In our previous studies, we found that IgG1 levels were increase...

Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma.

Immuno-oncology therapies represent a new treatment opportunity for patients affected by metastatic melanoma. The purpose of this study was to estimate the costs of immune-related adverse events (irAE...

Immuno-chemotherapeutic Increase of Peripheral Absolute Monocyte Count Predicts Interstitial Pneumonia in Lymphoma Patients.

Interstitial pneumonia (IP) is one of the potentially fatal adverse events for lymphoma patients undergoing immuno-chemotherapy. However, the risk factors and predictive markers remain unclear for thi...

Minimal Information About an Immuno-Peptidomics Experiment (MIAIPE).

Minimal Information about an Immuno-Peptidomics Experiment (MIAIPE) is an initiative of the members of the Human Immuno-Peptidome Project (HIPP), an international program organized by the Human Proteo...

Clinical Trials [1086 Associated Clinical Trials listed on BioPortfolio]

Exposure Chamber Trial With Cat Immunotherapy

The main purpose of this trial is to investigate if any of three different doses of cat hair immunotherapy is safe for treatment of cat allergic patients.

Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy

We wanted to examine the immunogenicity and safety of a shortened specific immunotherapy in contrast to the standard specific immunotherapy. Therefore, we challenged 12 patients for 14 we...

Study of the Cognition of Patients Treated With Immunotherapy

The investigator's longitudinal pilot study aims to evaluate for the first time the impact of immunotherapy on cognition in oncology. Due to the recent nature of immunotherapy, its side e...

Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy

The study evaluates the safety and effect of intralymphatic allergen specific immunotherapy in increasing doses. Patients that have already undergone subcutaneous immunotherapy will be tre...

Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma

The purpose of this study is to determine the safety of making and giving Epstein-Barr virus (EBV) immunotherapy products to subjects with nasopharyngeal carcinoma (NPC) associated with EB...

Companies [103 Associated Companies listed on BioPortfolio]

Bionor Immuno AS

Bionor Immuno is a multidisciplinary drug discovery company located in Skien, Norway. The major focus of the company is to develop effective peptide based immunotherapies, against infectious diseases ...

Bionor AS

Bionor is a biotechnology company founded in 1985 developing products for human and veterinarian medicine including aqua culture. For the last 10 years Bionor has increased its HIV related activities ...

Immuno Laboratories

Headquartered in Fort Lauderdale, Florida, Immuno Laboratories is widely recognized as one of the leading food and environmental allergy testing facilities in the world. Since 197...

Immunotech Laboratories, Inc.

Headquartered in Monrovia, CA, Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitati...


SDI is a leading healthcare market insight and analytics firm. It provides the industry’s most comprehensive de-identified patient-level data to pharmaceutical, biotech, reta...

More Information about "Bionor Immuno AS" on BioPortfolio

We have published hundreds of Bionor Immuno AS news stories on BioPortfolio along with dozens of Bionor Immuno AS Clinical Trials and PubMed Articles about Bionor Immuno AS for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Bionor Immuno AS Companies in our database. You can also find out about relevant Bionor Immuno AS Drugs and Medications on this site too.

Quick Search


Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Corporate Database Quicklinks

Searches Linking to this Company Record